English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Psilocybin for Depression: What the Johns Hopkins Trial Actually Found
If you've spent any time researching psychedelics as a way out of long-running depression, you've probably bumped into the Johns Hopkins name. There's a reason. A few years back, the team there ran the first proper randomized controlled trial looking at whether psilocybin — the active compound in magic mushrooms — could shift the needle for people who'd been clinically depressed for years. The results were striking enough that they're still shaping how plant medicine retreats, clinicians, and curious readers talk about psychedelic healing today. I want to walk you through what the study actually said, what it didn't say, and what any of it means if you're quietly weighing whether a psilocybin retreat is worth the time, money, and emotional bandwidth. No hype. No promises. Just the picture as it stands. The trial, published in JAMA Psychiatry, followed 24 adults with major depressive disorder. The average participant had been living with depression for over two decades — twenty-one and a half years, to be precise. That's not a bad month. That's a meaningful chunk of a human life spent under a grey ceiling. None of them were on antidepressants during the study, and none had bipolar disorder or schizophrenia, conditions that can make psychedelics genuinely dangerous. Each person did two dosing sessions, spaced about a week and a half apart. They swallowed a capsule — first a moderately high dose around 20 mg, then a higher 30 mg dose — put on eyeshades, lay back on a couch, and listened to a curated instrumental playlist while two trained facilitators sat with them. Around the sessions, participants also did eight hours of preparation beforehand and two hours of debriefing afterward. The drug was the catalyst, but the structure around it was the actual therapy. Here's what the researchers found. After the first session, 67% of participants reported their depression symptoms had dropped by more than half. After the second, that figure climbed to 71%. Four weeks out, 54% of participants no longer met the criteria for depression at all. In clinical language, they were in remission. For context: SSRIs — drugs like Prozac, Lexapro, Zoloft — are the standard first-line treatment for depression and have been since the late twentieth century. They work, sometimes well, by adjusting serotonin levels in the brain. But they don't work for everyone, and they don't work fast. NIH data suggests roughly 40 to 60 out of every 100 people see improvement after six to eight weeks on an antidepressant. If you're in a dark place right now, six to eight weeks is an eternity. The Hopkins team's headline claim was that psilocybin's antidepressant effect in their study was about four times greater than what's typically seen with traditional antidepressants. That's a big number, and it deserves to be treated carefully. The sample was tiny — 24 people. The participants skewed white, college-educated, and middle-class. Their depression was moderate rather than treatment-resistant in the most severe sense. And the follow-up at the time of publication was only four weeks. Plenty of treatments look great at four weeks and lose their shine by month six. Still — and this is the part worth sitting with — psilocybin appeared to do in two sessions what SSRIs sometimes can't do in two years. That's not nothing. That's the kind of signal that's quietly redrawing the mental-health map. SSRIs nudge brain chemistry over weeks. Psilocybin appears to do something more like a hard reset. Brain-imaging research suggests the compound temporarily loosens the grip of what's called the default mode network — the part of the brain associated with self-referential thinking, rumination, and the looping inner monologue that depression feeds on. When that network goes quiet, people often describe a sense of perspective they hadn't been able to access. The story they'd been telling themselves about who they are and what's possible suddenly seems editable. That's why facilitators talk so much about set and setting, and about integration afterward. The mushroom doesn't fix you. It opens a window. What you do with the view — the conversations you have with a therapist or a guide, the journaling, the behavior changes you actually make in the weeks that follow — is the part that determines whether anything lasts. People who treat psilocybin like a magic bullet tend to be disappointed. People who treat it as the start of a serious piece of inner work tend to do better. The Hopkins study was a clinical setting — sterile, structured, supervised by people with medical credentials. Most psilocybin retreats are not clinical settings. They're held in places where the medicine is legal or tolerated: Jamaica, the Netherlands, parts of Mexico, a handful of indigenous-led centers in South America. Some are excellent. Some are sketchy. The quality gap between the top tier and the bottom tier is enormous. If you're researching options, here are the things worth interrogating before you put down a deposit: A few things the research doesn't say, that I think get glossed over in the excited coverage. First, psilocybin isn't right for everyone. People with personal or family histories of psychosis, schizophrenia, or bipolar disorder face real risks. Certain heart conditions are a concern. Some SSRIs and other psychiatric medications interact with serotonergic psychedelics in ways that range from blunting the experience to causing serious problems — tapering, when appropriate, has to be done with a doctor, not a wellness blogger. Second, a high-dose session can be hard. Genuinely hard. People sometimes call them challenging experiences, which is polite shorthand for hours of confronting grief, fear, shame, or memories you'd buried for good reason. In a well-held container with skilled support, that confrontation can be healing. In a bad container, it can compound trauma rather than release it. Third, the research is still young. Most of what we have are small studies, encouraging signals, and a lot of careful optimism from serious scientists. We don't yet know how durable the effects are across years, how psilocybin interacts with the full spectrum of mental health conditions, or what the optimal protocols look like for different people. Anyone speaking with total certainty about any of this is either uninformed or selling something. If you're reading this because antidepressants haven't worked, or because you've been managing rather than living for longer than you'd like to admit, the Hopkins findings are a reasonable thing to take seriously. They're not a guarantee. They're permission to keep researching, to talk to a doctor or therapist who's actually willing to discuss psychedelics without flinching, and to consider whether a properly run retreat — with real preparation, real facilitation, and real integration support afterward — might fit into your bigger picture. For readers who want to take this further, a range of vetted psilocybin retreats from around the world can be browsed on our marketplace here. Choose carefully. The medicine is powerful. The container around it matters just as much.
Psilocybe Azurescens: The Most Potent Magic Mushroom and How It's Grown
If you've spent any time reading about psychedelic mushrooms, you've probably bumped into the name Psilocybe azurescens — usually wrapped in superlatives. The strongest. The wildest. The one that grows in the dunes. Most of that hype is actually true, which is rare for a corner of the plant-medicine world that loves a tall tale. Azurescens is a genuinely remarkable little mushroom with a short, strange history and a personality of its own. This is a closer look at where it came from, why it punches so hard, and what's involved if you ever wanted to grow it — written for the curious reader, not the commercial cultivator. Whether you're researching psilocybin out of personal interest or weighing it as part of a broader interest in psychedelics and master plants, knowing the basics about this species is worth your time. Azurescens is a wood-loving species native to a slim stretch of the Pacific Northwest coast in the United States — think the Oregon and Washington shoreline, where conifer debris, dune grass, and damp salt air meet. It's a relative newcomer to mycology. The species was formally described in 1996 by Paul Stamets and Jochen Gartz, after being noticed years earlier by a group of Boy Scouts camping near the mouth of the Columbia River. The story goes that one of them was Stamets' son. Whether that origin tale is fully accurate or partly folklore, the mushroom got its scientific name and its nickname — “Flying Saucer Mushroom,” for the wavy, UFO-shaped caps it produces in cool weather. What sets azurescens apart isn't its looks, though. It's the chemistry. By dry weight, this species contains some of the highest concentrations of psilocybin, psilocin, and baeocystin ever measured in a wild mushroom. Roughly speaking, it tests at around three times the potency of the more familiar Psilocybe cubensis — the species behind nearly every store-bought grow kit and most underground supply. That fact alone is responsible for a lot of azurescens' reputation, and a lot of trouble for the unprepared. Caramel-brown caps that flatten out and develop a slight nipple in the centre. A whitish stem that bruises a vivid blue-green when handled — the classic signature of psilocybin-bearing species. Dark purple-brown spores. It tends to fruit in clusters on woody debris, often hidden under dune grass, between September and January when temperatures drop into single digits Celsius. Cold is part of its lifestyle, not an obstacle to it. Three times the strength of cubensis is not a marketing line — it's a practical warning. A dose of dried azurescens that would fit on a teaspoon can produce an experience that, with cubensis, would require a small handful. People accustomed to gauging mushroom doses by volume rather than weight have learned this the hard way. Reports of temporary paralysis at higher doses of azurescens circulate widely in mycology forums, and while the phenomenon isn't fully understood, it appears often enough that it deserves to be taken seriously. Beyond raw intensity, the experience is frequently described as more visual, more “alien,” and harder to steer than a comparable journey on cubensis. Whether that's pharmacology or expectation effect is up for debate. What isn't debatable is that this is not a beginner mushroom, and nobody should be approaching it as a casual weekend experiment. If you're newer to psilocybin and curious about the deeper end of the experience, a properly guided ceremony in a country where it's legal — Netherlands, Jamaica, certain parts of the U.S. — is a far safer doorway than a dune walk on the Oregon coast. People hear “most potent mushroom in the world” and immediately want to grow it. Understandable. The reality is that azurescens is one of the more demanding species in the genus to cultivate, and it doesn't reward shortcuts. Unlike cubensis, which colonises grain and fruits indoors on a rye-cake at room temperature in a few weeks, azurescens wants what it has in the wild: wood, cold, and patience. Here's the short version of how outdoor cultivation typically works: Indoor attempts using terrariums and refrigerated fruiting chambers exist, but the consensus among experienced cultivators is that azurescens is fundamentally an outdoor species. Trying to force it indoors usually means a long wait followed by disappointment. This is the part nobody likes. Psilocybin remains a controlled substance in most of the world, including the United States — yes, even though azurescens grows wild there. Cultivation, possession, and distribution carry real legal consequences in most jurisdictions. A small number of places have decriminalised personal use (Oregon, parts of Colorado, the Netherlands' truffle loophole), but “decriminalised” and “legal” are not the same thing, and the picture changes constantly. Before doing anything, check the law in your actual location, not the one you wish you lived in. There's a tendency in psychedelic circles to chase potency — to assume that stronger means better, deeper, more transformative. It doesn't. Some of the most useful psilocybin experiences happen at moderate doses with capable guides, in settings designed for integration. The reason a species like azurescens fascinates so many people isn't really about the milligram count. It's the romance of the wild — a powerful master plant fruiting on a windy beach in the rain, indifferent to anyone's intentions for it. If that romance is what's drawing you, it's worth asking what you actually want. Self-knowledge? Help with a stuck depression or an addiction pattern? Curiosity about consciousness? Each of those goals points toward different settings and different medicines. Ayahuasca ceremonies in the Peruvian Amazon, ibogaine programmes for opioid dependency, psilocybin retreats in Jamaica or the Netherlands — these are structured environments with people whose job is to keep you safe and help you make sense of what comes up. A wild-foraged batch of the world's strongest mushroom is the opposite of that. Plant medicines work best when you bring them context. Set, setting, and integration aren't buzzwords; they're the difference between an experience that reshapes your year and one that just shakes you. For readers who want to take this curiosity further in a held container rather than a solo experiment, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever path you choose, choose it with both eyes open — these mushrooms have been doing this far longer than we have, and they deserve some respect.
How Do Psychedelics Work? The Brain Science Behind the Trip
If you're researching a retreat, you've probably already read a hundred descriptions of what an ayahuasca night feels like. The visions. The purge. The crying, the laughing, the strange clarity at sunrise. What you've maybe not read — and what tends to matter once the romance fades and the booking deposit is staring back at you — is what these substances are actually doing in the brain that produces all of that. So let's get into it. Here's what the science currently says about how psychedelics work, in plain language, with the parts that are still guesswork clearly labelled as such. Whether you're considering ayahuasca for depression, psilocybin for stuck life patterns, or ibogaine for addiction, knowing the mechanism makes the experience less mysterious — and arguably safer to approach. The classical psychedelics — psilocybin (the active compound in magic mushrooms), DMT (the molecule that gives ayahuasca its punch), LSD, and mescaline (from San Pedro and peyote) — all share one core trick. They bind to a specific receptor in the brain called the 5-HT2A receptor. That receptor is normally the home of serotonin, the neurotransmitter that most people have heard of in the context of antidepressants. The psychedelic molecule shows up, fits the lock, and turns it — but it's not serotonin, and the neuron behaves differently as a result. Researchers have demonstrated this elegantly: give someone psilocybin alongside a drug called ketanserin, which blocks the 5-HT2A receptor, and the trip simply doesn't happen. No visuals, no ego dissolution, no insight. The molecule is still in your bloodstream. It just has nowhere to land. This is also why some psychedelics hit harder than others. LSD binds to the 5-HT2A receptor extremely tightly, which is part of why a microscopic dose produces a twelve-hour experience. Mescaline has additional dopamine receptor activity, which is part of why a San Pedro ceremony feels different from a psilocybin one — warmer, more embodied, less reality-shattering. Here's the finding that got the research world genuinely excited over the past decade. Psychedelics promote neuroplasticity — the brain's ability to physically rewire itself, growing new branches between neurons and forming new circuits. Why does this matter for someone considering a retreat? Because depression, addiction, and chronic anxiety appear to involve a kind of structural shrinkage in the brain. In depression specifically, the little branching extensions of neurons in the prefrontal cortex — the area that regulates mood and emotional response — literally wither. The neural architecture for flexible thinking and steady mood gets sparse. You stay stuck in the same grooves. Lab studies have shown that LSD and DMT cause those branches to regrow. In some experiments, the growth was more pronounced than what ketamine produces, which is notable because ketamine is already considered a breakthrough treatment for stubborn depression. Block the 5-HT2A receptor and the neuroplasticity vanishes too — same receptor, multiple effects. The practical takeaway: a single psychedelic experience may open a window of roughly two to four weeks during which the brain is unusually pliable. This is the integration window that experienced facilitators talk about. The substance does the chemistry; what you do in those weeks — therapy, journaling, ceremony, the hard conversations, new habits — is what carves the new grooves. Skip the integration and you've largely wasted the chemistry. The researcher Robin Carhart-Harris proposed something called the entropic brain hypothesis around a decade ago, and it's held up surprisingly well. The idea borrows from physics. Entropy is a measure of disorder, of unpredictability, of how many possible states a system can be in. Carhart-Harris and his team scanned people on LSD and psilocybin and found that brain activity becomes more entropic — less predictable, less locked into the familiar grooves. Normally-segregated brain regions start chatting with each other. The default-mode network, which is the chatterbox of the self, the inner narrator constantly running commentary about who you are and what people think of you, goes quiet. Without it, the boundary between self and not-self can blur. That's the famous ego dissolution. Carhart-Harris's framework places ordinary waking consciousness in a middle zone: If you accept this framing, depression and addiction look less like chemical imbalances and more like ruts. Psychedelics shake the system out of its rut by temporarily injecting chaos. The lasting benefits — increased openness, less rigid thinking, better ability to break habits — may come from that shake-up. Worth noting: this same mechanism is why bad sets and bad settings produce bad trips. A chaotic brain in a chaotic environment with unprocessed trauma in the room is not a peaceful evening. A 2019 study put participants in an EEG and measured what DMT — the same molecule that makes ayahuasca what it is — does to the brain's electrical rhythms. The findings explain a lot. Alpha waves, the brain rhythm associated with relaxed wakefulness, dropped sharply. Delta and theta waves, which dominate during dreaming, surged. In other words, the waking brain temporarily started running the same software it uses when you're deep in REM sleep, except the lights were on and the person was alert. The lead researcher described it as “dreaming with your eyes open,” which matches what people report after a strong DMT or ayahuasca experience almost word-for-word. This helps explain why ayahuasca visions feel so much more vivid and meaningful than ordinary imagination. You're not picturing things. You're dreaming things, in the same neurological sense as a sleeping dream, while conscious enough to engage with them and remember them. Back in 1954, Aldous Huxley took mescaline and wrote The Doors of Perception. He borrowed an idea from the philosopher C.D. Broad: the brain, Broad argued, doesn't create consciousness so much as filter it. There's more sensory and mental information available at any moment than you could possibly use, so the brain runs a reducing valve that narrows the firehose down to a manageable trickle. You see what helps you survive and ignore the rest. Huxley's claim was that psychedelics temporarily loosen the valve. More gets through. Colours, meanings, connections, memories, sensations the brain ordinarily suppresses as irrelevant. For seventy years this was a poetic metaphor. Then neuroimaging caught up. When researchers first scanned people on psilocybin, they expected to see more brain activity. Instead, certain hub regions — particularly the default-mode network — went quieter. With the filter dialled down, suppressed material can flood the conscious mind. This is, mechanistically, why people on ayahuasca recover memories they'd forgotten, see connections they'd missed, and confront emotional content they'd been managing to avoid for decades. None of this is academic if you're trying to decide whether to fly to Peru, Costa Rica, or the Netherlands and drink something that will rearrange your nervous system for a night. A few practical implications follow from the science: The science doesn't make psychedelics magic and it doesn't make them safe by default. It makes them a tool — a powerful one, increasingly well-understood, with a mechanism of action that genuinely lines up with the experiences people have been describing for thousands of years. The Amazonian shamans who built ayahuasca traditions didn't know about 5-HT2A receptors. They knew the medicine showed people what they'd been hiding from themselves. Turns out those are two ways of describing the same thing. If reading this has made you more curious rather than less, the next step is to look closely at specific retreats — their facilitators, their screening processes, their integration support — and find one that matches what you're actually after. A curated selection of ayahuasca and psychedelic plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. Whatever the brain is doing under these molecules, it deserves a thoughtful container around it.
Psychedelics as Medicine: What Science Actually Says About MDMA, Psilocybin, and Ketamine
Something genuinely strange is happening in medicine. Substances that landed people in jail a generation ago are now sitting in clinical trial pipelines, getting fast-tracked by regulators, and inspiring the kind of investor enthusiasm usually reserved for tech IPOs. If you've been quietly wondering whether psychedelics might help with depression, addiction, or trauma that hasn't budged in years — you are not imagining the shift. The science has been catching up to what indigenous traditions and a handful of stubborn researchers have been saying for decades. But the headlines run hot, and most retreat-seekers I talk to are not looking for hype. They want to know what's actually working, what's still experimental, and how any of it connects to the very real question of whether to fly to Peru, Costa Rica, or the Netherlands and sit in a ceremony. So here's the honest map — what current research suggests about MDMA, psilocybin, ketamine, and ayahuasca, and how that intersects with the world of plant medicine retreats. For roughly forty years after the cultural backlash of the late 1960s, serious psychedelic research basically stopped. Funding dried up. Careers were quietly ended. Then, around the early 2000s, a few research groups — Johns Hopkins, Imperial College London, NYU, MAPS — started getting permission to study these compounds again. The early results were strong enough that the conversation has, slowly, gone mainstream. What's driving the resurgence isn't just curiosity. It's that conventional psychiatry has hit a wall. SSRIs help some people some of the time. Talk therapy is essential but slow. Treatment-resistant depression, complex PTSD, end-of-life anxiety, and entrenched addiction remain stubborn problems that swallow lives. Psychedelics — for all their cultural baggage — appear to do something genuinely different at the neurological level. They appear to loosen the brain's habitual patterns in a way that lets people see their lives, and their pain, from outside the rut. This is the same territory that traditional plant medicine has worked with for centuries. The vocabulary is different. The framing is different. The underlying phenomenon may not be. Of all the psychedelic-adjacent compounds in research, MDMA has gone the furthest down the regulatory road. Studies running through MAPS (the Multidisciplinary Association for Psychedelic Studies) showed striking results — in some trials, around two-thirds to three-quarters of participants with chronic, treatment-resistant PTSD no longer met the diagnostic criteria after a course of MDMA-assisted therapy. These were people who had been suffering, in many cases, for over a decade. The mechanism makes intuitive sense to anyone who has done trauma work. MDMA temporarily quiets the fear response while keeping the patient lucid and able to talk. Combat veterans, sexual assault survivors, and first responders have described being able to revisit memories that, sober, were simply too overwhelming to approach. The therapy isn't the drug — it's the trauma processing that the drug makes possible. It's not risk-free. MDMA raises blood pressure and body temperature, can cause insomnia for days afterwards, and is genuinely dangerous outside a medical setting where dose and purity are controlled. Recreational ecstasy is not the same thing as a measured dose in a clinical room with two therapists present. That distinction matters. Researchers studying psilocybin — the active compound in magic mushrooms — have used phrases like "surgical intervention" to describe what a single high dose, in the right setting, can do to depression. That's not marketing language. It comes from clinicians watching cancer patients with crushing end-of-life anxiety report durable shifts in mood and outlook after one or two sessions. Brain imaging gives a partial explanation. Depression seems to involve over-activity in the brain's default mode network — the circuit that runs rumination, self-criticism, and the looping replay of regrets. Psilocybin appears to temporarily dial that network down, which is part of why people describe a sense of "ego dissolution" during the experience. When the ego comes back online a few hours later, the grooves it ran in seem, for a while, less deep. A handful of well-funded biotech companies are now running large psilocybin trials for treatment-resistant depression. The serious researchers in the field believe a psilocybin-based prescription medicine could be approved before the end of this decade. In the meantime, psilocybin retreats have opened legally in the Netherlands (where truffles remain legal), Jamaica, and a growing number of jurisdictions in the Americas. Ketamine is the odd one out — technically a dissociative anesthetic rather than a classical psychedelic, but its rapid antidepressant effects have been hard to ignore. A nasal spray version called Spravato has been an approved depression treatment in the United States for several years now, specifically for severe depression that hasn't responded to other medications. What's notable about ketamine is the speed. Conventional antidepressants can take six weeks to do anything. Ketamine can lift suicidal ideation within hours. That's a different category of intervention — closer to emergency medicine than to maintenance therapy. The mechanism involves a brain receptor system (the NMDA pathway) that older antidepressants largely ignored. Ketamine clinics have proliferated quickly, which is both encouraging and worth approaching carefully. The quality of the integration and therapeutic container varies wildly. A ketamine infusion in a strip-mall clinic with no follow-up support is a different experience from ketamine-assisted psychotherapy with a skilled practitioner. Ayahuasca hasn't gone through the same Western regulatory pipeline as MDMA or psilocybin, partly because it's a brew rather than a pharmaceutical molecule, and partly because its cultural home is in indigenous Amazonian practice rather than a lab. But early research — much of it coming from Brazilian institutions and observational studies of long-term churchgoers in syncretic traditions like Santo Daime and the UDV — points in directions that align with what's being seen for psilocybin. Reductions in depression and anxiety scores. Shifts in addictive patterns. A common report of having been shown something true about one's own life. Ayahuasca contains DMT, which is structurally similar to psilocybin and serotonin, alongside MAO inhibitors from the caapi vine that allow it to work orally. The pharmacology is real. The ceremonial container, in traditional settings, is what allows the pharmacology to land therapeutically. This is the piece that gets lost in the rush to medicalize. The drug is part of the medicine. The space, the music, the facilitator, the dieta beforehand, and the integration afterwards are the rest of it. A retreat done well bundles those elements; a retreat done poorly hands you a cup of brew and hopes for the best. Reading the research can make you feel like the answer is obvious — book a retreat, fix the depression, change your life. The reality is more textured. A few things worth holding in mind: The research is real and it's promising. It is not a guarantee, and it does not replace the slow work of becoming a different person. What psychedelics — in clinical settings or in traditional ceremony — seem to offer is an opening. A few hours in which the usual self loosens its grip enough that something new can be glimpsed. Whether that glimpse becomes a life depends on what gets built around it. If you're somewhere on the spectrum from curious to quietly desperate, treat the decision the way you'd treat any other significant medical and personal choice. Read widely. Talk to people who've actually sat. Vet facilitators carefully. Take the preparation and the aftercare as seriously as the ceremony itself. For readers who want to take this further, a range of vetted ayahuasca and plant medicine retreats can be browsed on our marketplace here, with details on facilitators, traditions, and the kind of work each container is designed for.
Psychedelics for Depression and Addiction: What the Research Actually Shows
Picture a quiet room in Manhattan. A low brown couch, a small Buddha statue, hand-painted dishes on a side table. It looks like someone's grandmother's living room from 1974. It is, in fact, the setting where some of the most surprising mental-health research of the last decade has unfolded — a place where cancer patients have swallowed a capsule of psilocybin and walked out hours later describing the experience as one of the most meaningful of their lives. This is the strange, hopeful frontier of psychedelics and psychedelic-assisted therapy. After decades of being treated as cultural contraband, substances like psilocybin, ayahuasca, ibogaine, and MDMA are being studied seriously again — and the early data on depression, anxiety, and addiction is hard to ignore. If you've found your way here because you're quietly wondering whether plant medicine might help with something you've been carrying for years, you're not alone. A lot of people are wondering the same thing. The reason scientists keep using words like “breakthrough” and even “surgical intervention” when they talk about psychedelics isn't hype. It's that a single dose, given in the right setting with trained support, seems to do what years of daily SSRIs sometimes can't — particularly for people stuck in the deepest grooves of despair. In one well-known trial at NYU and Johns Hopkins, cancer patients with severe end-of-life anxiety were given psilocybin alongside therapy. The majority reported sustained relief from depression and existential dread months later. Not a slight improvement. A genuine shift. Many of them ranked the experience among the top five most meaningful events of their entire lives — comparable to the birth of a child or the death of a parent. That's an unusual thing to hear from a clinical trial. Pharma research doesn't usually produce results that read like a memoir. Here's a way to think about depression that helped me understand why psychedelics seem to do what they do. Imagine your brain as a city, full of roads. Some are well-worn highways used a thousand times a day — your habitual thoughts, your self-criticism, your story about why you're not enough. Other roads are barely paved, rarely traveled. In a depressed brain, the highway traffic gets stuck. Rush hour, all day, every day. Researchers at Imperial College London have shown that psychedelics appear to do something genuinely strange — they reduce traffic on the overused routes and send neural activity skittering down the empty ones. Connections form between regions of the brain that normally don't talk to each other. The cogs, as one researcher put it, get loosened. That loosening is often what people describe afterward. The rumination quiets. The sense of being trapped inside one narrow story about yourself softens. For a few hours, the mind escapes the rut — and sometimes, the new perspective sticks. The addiction research is where things get especially interesting. Addiction, like depression, is partly a story of stuck patterns — the same circuits firing, the same craving, the same coping behavior on repeat. Substances like ayahuasca, ibogaine, and psilocybin appear to interrupt those loops, sometimes dramatically. Ibogaine, derived from the iboga root of West Africa, has the longest underground reputation for treating opioid dependence. People who've gone through ibogaine treatment often describe a long, difficult inner journey — sometimes 24 to 36 hours of intense visions — followed by a striking reduction in withdrawal symptoms and cravings. It's not magic, and it's not without serious cardiac risks that require medical screening. But for people who've tried everything else, it's often the first thing that's actually worked. Ayahuasca, the Amazonian brew built around the Banisteriopsis caapi vine, has a different shape but a similar effect on certain people. The ceremonies are long, communal, and held by experienced facilitators in traditions that stretch back generations. Many participants come specifically because of addiction — to alcohol, to cocaine, to the quieter addictions of overwork and self-loathing — and leave with a fundamentally different relationship to whatever they were running from. The category of plants and brews used this way is sometimes called the master plants: teachers in the Amazonian sense, not chemicals to be consumed casually. That framing matters, because it shapes how the experience is approached — with preparation, respect, and a willingness to actually listen to what surfaces. This is the question almost everyone researching a retreat wants answered honestly, so let's be honest. A psychedelic ceremony — whether it involves ayahuasca, psilocybin, or San Pedro — is not a euphoric night out. It can be uncomfortable. It can be physically demanding. With ayahuasca specifically, vomiting (called la purga) is common and considered part of the healing. People often describe an initial wave of fear or disorientation. One man I spoke with, a sailor who'd done a Johns Hopkins psilocybin trial, compared the early part of his experience to falling off his boat in open ocean — looking back and finding the boat gone, then the water gone, then himself gone. Terrifying, in the moment. He came through it, with help from his facilitators, into something he still can't quite describe — a sense of being witness to life itself, free from the constant management of being a self. That arc — through difficulty, into something larger — is common. It's why a good retreat isn't just about the medicine. It's about who's holding the space. If you're considering a retreat, this is where to spend your attention. The medicine matters less than the container around it. Here's what experienced facilitators and seasoned participants tend to look for: One more thing: be skeptical of anyone who promises outcomes. Real facilitators talk about possibilities and risks. Sales pitches talk about transformation guaranteed. It depends entirely on where you are and what plant you're talking about. In the United States, psilocybin is federally illegal but decriminalized in cities like Denver, Oakland, and parts of Oregon, where supervised therapeutic use is now permitted under state law. Ayahuasca is federally illegal except for specific religious exemptions granted to the União do Vegetal and Santo Daime churches under a 2006 Supreme Court ruling. Outside the U.S., the landscape opens up. Peru, Costa Rica, the Netherlands, Jamaica, Mexico, and Brazil each host legal or tolerated retreat scenes for various plant medicines. Most serious retreat-seekers end up traveling, both for legal reasons and because the lineages are stronger where the plants come from. Plant medicine isn't for everyone. People with personal or family histories of schizophrenia, bipolar disorder, or psychotic episodes are generally advised to avoid classical psychedelics. Certain heart conditions rule out ibogaine. SSRI users typically need to taper off well before drinking ayahuasca, under medical guidance. And then there's the harder caveat: a single ceremony, no matter how profound, isn't a cure. It's a doorway. Whatever you see inside still has to be carried back into your daily life — your relationships, your work, your habits. The people who get the most lasting benefit are almost always the ones who do the integration work afterward, often with a therapist who understands psychedelics. For readers who want to take this further, a range of curated ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, take your time with the decision — this is one of those choices that rewards patience and punishes impulse.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Iboga and Ibogaine: What an Honest First Retreat Actually Looks Like
The first thing anyone who has sat with iboga will tell you is that it doesn’t feel like the other plant medicines. Ayahuasca moves like a river. Psilocybin opens like a door. Iboga sits you down in a hard chair, switches on a projector, and walks you through your own life — frame by frame — without much sympathy and without much hurry. If you’re researching an iboga or ibogaine retreat because something in your life has stopped working — an addiction you can’t shake, a depression that won’t lift, a grief you can’t name — it’s worth understanding what you’d actually be signing up for. This isn’t a glamour piece. Iboga is one of the most physically demanding psychedelics and plant medicines a person can take, and it’s also one of the most effective tools we currently know of for breaking certain kinds of addiction. Both of those things are true at once. Let’s get into what that really means. Iboga is the root bark of Tabernanthe iboga, a shrub native to the equatorial forests of Gabon and the surrounding region. In Bwiti tradition — the spiritual practice that has used iboga for centuries — it’s considered a master plant and a teacher, not a party drug or a quick fix. Ceremonies are long, sober, and structured. They’re also nothing like an ayahuasca ceremony, even though both fall under the broad banner of plant medicine. Ibogaine is the principal alkaloid extracted from the bark. It’s the form used in most clinical and semi-clinical addiction-recovery settings, particularly for opioid dependence. The science here is genuinely interesting: ibogaine appears to reset certain neural pathways involved in craving and withdrawal, and many people who go through a single session report that the physical pull of opioids is dramatically reduced afterward. That’s not marketing. That’s what shows up in interviews with participants and in the small body of clinical research that exists. The trade-off is that ibogaine is cardiotoxic in a way most psychedelics are not. It can affect heart rhythm, and people have died from it — almost always when proper medical screening was skipped. This is the single most important fact about ibogaine, and any retreat that doesn’t require an EKG, bloodwork, and a serious medical questionnaire before accepting you is a retreat you should walk away from. Most ayahuasca ceremonies run four to six hours. An iboga session runs anywhere from twenty to thirty-six. You don’t sleep. You don’t move much. You lie on a mat or a low bed in a quiet, dim room, and the medicine takes you somewhere very specific. People describe the early hours as a kind of buzzing, with a high-pitched ringing in the ears and a sense that gravity has doubled. Then the visions start — but not the kaleidoscopic geometry of mushrooms or the spirit-realm of ayahuasca. Iboga visions tend to be cinematic and biographical. Old memories. Faces of people you wronged. Decisions you made at nineteen that you’ve been pretending not to think about. It plays them back without commentary, and you watch. One person I interviewed described it as “sitting through a documentary about myself, produced by someone who has access to every file.” That’s about right. The medicine doesn’t shout. It doesn’t need to. It just shows you what’s there, and lets you draw your own conclusions. The physical side is no joke either. Nausea is common. Ataxia — loss of coordination — is universal; you genuinely cannot walk. Most people don’t want to. You stay lying down, eyes closed, for the entire experience, with a facilitator nearby monitoring vital signs and occasionally bringing water. The population at iboga retreats skews different than at ayahuasca centers. You’ll meet fewer wellness tourists and more people who have run out of other options. In rough strokes: What unites them is a particular kind of seriousness. Iboga isn’t a weekend. It’s closer to elective surgery on your psyche, and the people who choose it tend to know that going in. This is the use case that gets the most attention, and rightly so. For opioid dependence specifically, ibogaine appears to interrupt withdrawal in a way nothing else really does. Participants describe coming out of a session no longer feeling the physical craving that had defined their daily life for years. The window this opens — usually a few weeks to a few months — is when the real work happens. The medicine doesn’t do the work for you. It makes the work possible. Recovery rates vary wildly depending on what happens after the session. Retreats that send you home with no follow-up have poor long-term outcomes. Retreats that integrate ibogaine into a longer program — aftercare calls, therapy, sober community, sometimes a follow-up booster session — show much better numbers. The choice of retreat matters more than almost anything else. It’s also worth being honest: ibogaine isn’t magic. Some people relapse. Some find it doesn’t take. Some have profound experiences that don’t translate into behavior change. Psychedelic-assisted recovery is a tool, not a cure, and any retreat that promises a cure is misrepresenting what they can offer. This is the section to read twice. Iboga and ibogaine retreats vary enormously in quality, and the consequences of choosing badly are higher than with other plant medicines. Cost varies. A serious ibogaine-for-addiction retreat with proper medical infrastructure typically runs between five and ten thousand dollars for a week or two. Traditional Bwiti ceremonies in Africa can be less expensive but require considerably more cultural adaptation. Free or very cheap iboga is almost always a warning sign. Iboga rewards preparation. In the weeks before a session, most retreats ask you to taper off pharmaceuticals (under medical supervision), eat clean, abstain from alcohol and other substances, and start journaling about what you’re bringing to the medicine. The dieta is less elaborate than ayahuasca’s, but the principle is the same: arrive empty so the medicine has room to work. Mentally, the best preparation is honesty. Sit down before you go and write — actually write, on paper — what you want to look at. The patterns you’re tired of. The fears you’ve been avoiding. Iboga will likely show you all of it anyway, but going in with your eyes already open changes the quality of the experience. Afterward, expect to feel scoured. Many people describe a few weeks of unusual clarity, followed by the slow return of regular life. What you do with that clarity window is the whole game. Therapists who specialize in psychedelic integration are worth their weight in gold during this period. If you’ve read this far, you’re probably not casually curious — you’re weighing a real decision. For readers who want to take this further, a range of vetted ibogaine and iboga retreats can be browsed on our marketplace here. Whatever you decide, decide slowly, ask hard questions, and choose the people running the ceremony as carefully as you’d choose a surgeon. With this medicine, that’s not an exaggeration.
Psilocybin Therapy in Oregon: What Legal Access Actually Looks Like
A few years back, the idea of legally sitting with psilocybin mushrooms — in a licensed space, with a trained facilitator, without breaking any laws — sounded like wishful thinking. Then Oregon happened. In November 2020, voters there passed Measure 109, and the state became the first in the U.S. to create a regulated framework for supervised psilocybin use. The rollout has been slow, messy, and fascinating. And if you're someone weighing whether psychedelics might help with depression, trauma, or just a stuck patch of life, what's unfolded in Oregon matters. This isn't a political post. It's a practical one. I want to walk through what Oregon actually legalized, how it fits into the broader psychedelic renaissance, where it leaves people who can't fly to Portland, and what to keep in mind if you're considering plant medicine or psilocybin in a retreat setting. There's a lot of hype out there. The reality is more interesting — and more nuanced — than the headlines suggest. Here's the short version. Measure 109 didn't make psilocybin legal in the way alcohol or cannabis is legal in some states. You can't walk into a dispensary and buy dried mushrooms. You can't grow them at home for personal use without risk. What the measure created was a tightly controlled service model: licensed facilitators, licensed service centers, and clients who go through a preparation session, a dosing session, and an integration session — all on-site, all supervised. You don't need a diagnosis to participate. That's a meaningful detail. Unlike most clinical trials, where you have to qualify with treatment-resistant depression or end-of-life anxiety, Oregon's framework treats psilocybin services as a wellness offering open to adults. Whether that's a feature or a bug depends on who you ask. The state's Psilocybin Services program took its time to write the rules. The first licensed service centers opened in 2023, and as of 2026 there's a working — if still small — network of providers across the state. Prices for a full session run from about $1,500 to $3,500, sometimes more, which is a real barrier and one of the loudest criticisms from advocates who pushed for decriminalization instead of (or alongside) legalization. Oregon didn't happen in a vacuum. For years, researchers at Johns Hopkins, NYU, Imperial College London, and elsewhere have been publishing studies showing that psilocybin — given in a supportive setting, with proper preparation — can produce striking reductions in depression and anxiety, including in people who haven't responded to conventional treatment. The cancer-patient studies got the most press, but the work on major depression and on alcohol-use disorder has been just as compelling. That research is what cracked the door open. Decriminalization measures in Denver, Oakland, Santa Cruz, Ann Arbor, and a growing list of other cities pushed it open further. Then Oregon legalized supervised access. Colorado followed with Proposition 122 in 2022, which created its own regulated framework plus broader decriminalization of several plant medicines, including DMT and mescaline. The picture across the U.S. is now a patchwork. Federally, psilocybin remains a Schedule I substance. State by state, city by city, the rules shift. If you're researching options, the legal landscape where you live is worth checking carefully — not because anyone's likely to kick down your door, but because where the law sits affects which providers operate openly, what kind of training they've had, and what recourse you have if something goes wrong. People imagine a lot of things when they hear “legal mushroom therapy.” The reality is quieter than the imagination. A typical session at an Oregon service center looks something like this: It's not a party. It's not a quick fix. People who walk in expecting fireworks sometimes leave underwhelmed; people who walk in with humility and a real question often leave changed. Your experience depends on dose, set, setting, and frankly your nervous system on the day. The medicine doesn't perform on demand. If you're researching psychedelic options seriously, you've probably noticed that psilocybin isn't the only path on the table. Ayahuasca retreats in Peru, Costa Rica, and increasingly in legally permissive corners of Europe; ibogaine clinics in Mexico for people working through opioid addiction; San Pedro and huachuma ceremonies in the Andes; psilocybin retreats in Jamaica, the Netherlands, and now Oregon. Each tradition carries its own culture, its own risks, its own kind of work. Psilocybin tends to be the gentler doorway. The experience is usually shorter, the body load lighter, the integration arc more manageable for first-timers. Ayahuasca is longer, more physical (yes, the purging is real), and rooted in lineages worth understanding before you sign up. Ibogaine is a different animal entirely — powerful for addiction interruption, but with real cardiac risks that require medical screening. The point isn't to rank them. The point is that the choice should match what you're actually working on. Someone navigating grief and mild depression might find a supervised psilocybin session to be exactly the right size. Someone wrestling with deep generational trauma or long-term substance dependence might be better served by a longer-format plant-medicine retreat with experienced facilitators. There's no universal answer here. Whether you end up booking a psilocybin session in Oregon, an ayahuasca retreat in the Sacred Valley, or something else, the same questions apply. The legal status of a place is one signal. It's not the only signal, and sometimes not the most important one. Cost is real. So is travel. So is the question of how much time you can take afterward to actually let the experience land. A weekend session jammed between two stressful work weeks is a waste of money and an unkindness to yourself. I've sat across from a lot of people considering their first psychedelic retreat. The ones who tend to do well aren't the bravest or the most spiritually fluent. They're the ones who know why they're going. Not in a grand way — just specifically. “I want to look at what happened with my father.” “I want to know if I can stop drinking.” “I've been depressed for three years and nothing has moved.” A clear question makes for clearer work. The ones who struggle are usually running from something rather than toward something, or they've heard psilocybin called a miracle and they want the miracle. The medicine doesn't reward that posture. It tends to show people exactly what they've been avoiding, which is rarely comfortable and almost always useful in the long run. Oregon's experiment is still young. The price point will likely come down as more centers open and competition grows. The model itself — supervised, integrated, deliberately slow — is probably closer to what responsible psychedelic care looks like than either the underground or the pharma-clinical-trial extremes. Whether you go that route, choose a traditional ayahuasca retreat abroad, or stay home and read a few more books before deciding, the honest move is the same: get specific about what you want, get honest about your medical realities, and don't outsource the decision to a marketing brochure. If something here is sitting with you and you want to look at concrete options, a curated range of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with it. The retreat will still be there next month, and the question of whether you're ready is worth more than a quick yes.
When MDMA Cracked Open a White Supremacist: What One Study Reveals About Psychedelic Healing
A man named Brendan walked into a research lab in early 2020. He was, at that point, a known figure in American white nationalism — he'd helped organize the Charlottesville rally three years earlier, and his name was already a liability in his own life. The study he signed up for had nothing to do with hate or healing. The researchers wanted to know whether MDMA made human touch feel more pleasant. That was it. A small, almost banal question. Then Brendan took the dose. And somewhere in the next few hours, something in him cracked open. He went home, wrote a note to the team, and told them — in so many words — that he was done. Done with the movement. Done with the worldview. He wrote that he now knew what he needed to do, and suggested they Google him to understand why that mattered. They did. And the researchers were, understandably, alarmed before they were astonished. This story keeps surfacing in conversations about psychedelics, addiction, and the broader question of whether plant medicines and synthetic compounds like MDMA can actually shift the architecture of a person's beliefs. It's a striking anecdote. It's also wildly easy to misread. So let's slow down and look at what happened, what it might mean, and what it almost certainly doesn't. The trial, run by Harriet de Wit at the University of Chicago, wasn't a therapy protocol. There was no facilitator guiding Brendan through trauma, no integration coach waiting on the other side. It was a touch-perception study — neutral, clinical, fluorescent-lit. Brendan received MDMA and did the tasks. The transformation, such as it was, happened on his own time, in his own head. What he reported afterward was simple and almost embarrassed: the drug made him feel love, and in the warmth of that feeling, the rigid scaffolding of his ideology stopped making sense. He described asking himself, in the middle of the experience, why am I doing this? The question wasn't intellectual. It came from somewhere lower, somewhere more honest than argument. He didn't renounce his beliefs that afternoon in any dramatic public way. The shift was quieter, and it unfolded over months. He distanced himself from his old network. He started talking, carefully, to people he'd previously written off as enemies. The researchers, who only learned about his background after the fact, ended up watching one of the strangest case studies in psychedelic science assemble itself in real time. No. And anyone who tells you it does is selling something. Here's the thing about MDMA and the classical psychedelics — ayahuasca, psilocybin, LSD, San Pedro, ibogaine. They don't carry content. They don't have politics. They amplify whatever is already inside a person and crank up the emotional volume on it. A 2021 paper in Frontiers in Psychology made this point bluntly: psychedelics are non-specific amplifiers. Give the same dose to a hateful person and a generous one, and you'll get more hate or more generosity, not a clean reset. What seems to have happened with Brendan is more interesting than a chemical exorcism. The MDMA didn't delete his beliefs. It opened a window — briefly, vividly — onto another way of feeling about other people. And once you've felt something, you can't quite un-feel it. The seed of doubt gets planted. Whether it grows depends on everything that happens after. Researchers studying MDMA-assisted therapy for PTSD have noticed something similar. The drug's role is to soften the defensive crust around painful material so the person can actually look at it. The looking is what does the work. The compound is the door, not the room. If you've ended up on this page, there's a decent chance you're carrying something heavy — an addiction that won't budge, a depression that's settled in like weather, a pattern in your relationships you can see clearly and still can't change. The Brendan story matters to you for one specific reason: it suggests that even deeply embedded ways of being can sometimes shift faster than we think. Plant medicines and psychedelics — including ayahuasca and the so-called master plants of the Amazon — work on a similar logic. They don't deliver answers. They loosen the grip of a worldview just enough for the person to glimpse alternatives. People in ceremony describe seeing their addiction from the outside for the first time, or recognizing that a story they've been telling themselves since childhood was never actually true. Ayahuasca, in particular, has a reputation for showing people themselves with uncomfortable clarity. What's worth saying out loud: this softening is real, and it's also dangerous if it happens in the wrong setting. Brendan got lucky. The researchers were thoughtful, the dose was clean, and he had enough inner ground to do something constructive with the experience. Plenty of people don't. A weekend retreat without proper screening, or a ceremony led by someone with more charisma than skill, can leave a person more raw than healed. I've sat in a lot of ceremonies and talked to a lot of facilitators, and the honest version of the retreat conversation looks like this: Costs vary wildly. A week-long ayahuasca retreat in Peru might run anywhere from $1,500 to $4,000 depending on the center, the lineage, and the level of medical and psychological support on-site. Ibogaine programs — which are used specifically for opioid addiction in some clinics — tend to run higher because they require medical monitoring. Psilocybin retreats in legal jurisdictions like the Netherlands or Jamaica sit in a middle range. Brendan's story isn't a feel-good fable about a magic pill that fixes broken people. It's something quieter and more useful. It's a reminder that the human capacity for change isn't always proportional to the size of the problem. Sometimes a person carries a worldview for decades and then, in the space of a few hours, sees through it. That doesn't happen because of a chemical. It happens because the chemical briefly lifts the defenses we use to avoid feeling things — and what's underneath those defenses, in most of us, is closer to love than to hate. Closer to grief than to anger. Closer to a desire to belong than to a need to be right. Whatever you call it — the self, the soul, the deeper layer — it tends to be more humane than the personality we've built on top of it. For people considering plant medicine to address addiction, depression, or patterns that feel cemented in, this is the honest promise. Not a cure. Not a guarantee. Just the possibility that what feels permanent might be more porous than it looks, given the right setting and the right support. For readers who want to take this further, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Brendan, last anyone heard, was still doing the work. That's the part of his story that gets quoted least and matters most. The drug opened a door. He's the one who kept walking through it.
Inside Oregon's Legal Psilocybin Experiment: What It Means for Psychedelic Retreats
Something quietly historic is happening in Oregon. While most of the United States still treats psilocybin mushrooms as a Schedule I substance, this one state on the Pacific coast is busy building the country's first legal, regulated framework for psilocybin services. Not decriminalisation. Not a research carve-out. An actual, licensed system where adults can sit with psilocybin under the care of a trained facilitator. For anyone weighing a psychedelic retreat — especially folks who've been reading about psilocybin for depression, end-of-life anxiety, or stubborn patterns that no amount of talk therapy has shifted — Oregon matters. It's the closest thing we have to a working blueprint. And the people building it are doing so in real time, in public, with all the messiness that involves. Back in 2020, voters passed Measure 109, the ballot initiative that authorised the creation of a legal psilocybin services program. It didn't legalise mushrooms in the supermarket sense. What it did was open a narrow but very real door: adults aged 21 and over could, eventually, consume psilocybin at licensed service centres under the supervision of trained facilitators. No prescription required. No specific diagnosis required. That last part is what makes the Oregon model genuinely novel. Other psychedelic pathways being developed in the U.S. — MDMA for PTSD, psilocybin for treatment-resistant depression — are medical models, gated by diagnosis and FDA approval. Oregon's program is a services model. The state regulates training, product, and venues, but the experience itself sits closer to a ceremony than a clinic visit. That distinction matters more than it first appears. Two main bodies have done the heavy lifting. The Oregon Psilocybin Advisory Board drafted recommendations covering everything from facilitator training requirements to product testing standards. The Oregon Health Authority, through its Oregon Psilocybin Services division, turned those recommendations into actual rules. The first legal sessions began taking place in 2023, and the program has been expanding — and learning hard lessons — ever since. A program like this doesn't appear out of nowhere. It's the product of a small, identifiable group of people — campaign organisers, attorneys, regulators, therapists, and entrepreneurs — who spent years pushing the boulder up the hill. A few names worth knowing if you're trying to understand how this market actually works. Tom Eckert and the late Sheri Eckert were the chief petitioners behind Measure 109. Tom went on to chair the advisory board during the early rulemaking, then stepped away amid questions about board-member conflicts of interest — an early reminder that this industry has the same political mess as any other. He now directs work at InnerTrek, one of the larger psilocybin-facilitator training programs in the state, and at the Sheri Eckert Foundation, which funds scholarships for people who want to train as facilitators but can't afford the tuition. Sam Chapman managed the Measure 109 campaign and now leads the Healing Advocacy Fund, a nonprofit that's stayed deeply involved in implementation. David Bronner — yes, the soap guy — poured roughly $2 million of Dr. Bronner's money into passing the measure and has continued funding training programs, harm-reduction work, and equity initiatives. His company has put tens of millions into drug-policy reform over the years, which is not the kind of detail you forget once you've seen it on a bottle of peppermint castile. On the regulatory side, André Ourso and Angela Allbee at the Oregon Health Authority have been the people actually translating a ballot measure into a working program. Ourso previously oversaw the rollout of Oregon's cannabis market, which gave the state at least some institutional muscle memory for standing up a regulated controlled-substance industry. Allbee manages day-to-day operations of Oregon Psilocybin Services, which is the part of state government that issues the licences and writes the rules. One of the most interesting fights inside Oregon's program has been about facilitators — who they are, how they're trained, and how much it costs to become one. This isn't a side debate. It's the whole ball game. Jon Dennis, an attorney and cofounder of the Entheogenic Practitioners Council of Oregon, has been a persistent voice arguing that religious, spiritual, and community-based practitioners should have a meaningful role in the legal program. His worry — and it's a reasonable one — is that if facilitator training is structured like a graduate degree, with the price tag to match, the only people serving clients will be affluent therapists, and the cost of a session will price out the people who most need access. Angela Carter, a vice chair on the advisory board, has pushed similar equity and harm-reduction priorities from inside the regulatory process. At the same time, organisations like Fluence — cofounded by Ingmar Gorman and Elizabeth Nielson, both psychologists who worked on MDMA-assisted therapy trials — have been building rigorous clinical-style training programs aimed at therapists who want to add psilocybin work to their practice. Both visions are defensible. Both are getting built. How they coexist will shape what an Oregon psilocybin session actually feels like. Here's the practical takeaway for someone in the research phase. Oregon's legal program is not a retreat in the Costa Rica or Peruvian-jungle sense. Most licensed service centres offer a single session — preparation meeting, dosing day, integration meeting — rather than a multi-day immersive experience. Prices have settled in the rough neighbourhood of $1,000 to $3,500 for the full arc, depending on the facilitator, the venue, and the dose. That's lower than some international retreats and considerably higher than others. If you're weighing your options, a few honest things worth holding in mind: Colorado followed Oregon's lead with its own psychedelic-services initiative, passed in 2022 and now rolling out. Other states are watching closely, drafting bills, and quietly preparing legislation. The federal picture remains murky — psilocybin is still Schedule I, and the DEA hasn't softened its public stance — but the state-level momentum is real, and it's not slowing down. What Oregon proves, more than anything, is that a regulated psychedelic services market is possible. Not easy. Not without its conflicts of interest, equity gaps, and growing pains. But possible. For readers who've spent years assuming plant medicine meant flying to South America or knowing the right underground guide, that's a meaningful shift. It's also worth saying plainly: a legal framework doesn't make psilocybin right for everyone. People on certain antidepressants, people with personal or family histories of psychosis, people in acute crisis — these are situations where a thoughtful provider will tell you to wait, or to look at other tools first. The most useful question isn't where to do this work but whether now is the time, and with what kind of support around you. If you're somewhere in that weighing phase, it can help to see what's actually on offer — different settings, different traditions, different price points — before committing to anything. A curated set of psilocybin and plant-medicine retreats can be browsed on our marketplace here, which is a low-pressure way to compare what's out there while you keep doing your homework. Oregon's experiment is young. The facilitators are still learning. The regulators are still adjusting. But the door is open in a way it wasn't five years ago, and the people who pushed it open deserve some credit for that — even when the politics behind the scenes have been less than tidy.
Ketamine for Depression: What the Latest Trial Results Mean
Ketamine, a medication primarily used as an anesthetic, has been explored as a potential treatment for severe forms of depression. Its fast-acting nature makes it an attractive option for patients experiencing sudden bouts of suicidality. However, the latest trial results from Atai Life Sciences, a leading company in the field of psychedelics, have raised questions about its efficacy. The trial, conducted by Perception Neuroscience, a subsidiary of Atai, involved 102 patients with treatment-resistant depression. These patients were administered either a 60mg dose of PCN-101, a 30mg dose, or a placebo. The results showed that patients who received the 60mg dose did not experience significant improvement in their depression symptoms compared to those who received the placebo. This outcome is particularly noteworthy given the current landscape of depression treatment. With many patients not responding to traditional therapies, the search for alternative treatments is urgent. Ketamine, with its unique mechanism of action, had been seen as a promising candidate. The failure of this trial, however, underscores the complexity of treating depression and the need for continued research. The trial's methodology involved administering the drug intravenously and then assessing the patients' depression symptoms 24 hours later using the Montgomery-Åsberg Depression Rating Scale. The lack of significant improvement in the treatment group compared to the placebo group is a critical finding. It suggests that, at least in the context of this study, ketamine may not offer the therapeutic benefits that were hoped for. The implications of this trial are multifaceted. For patients and their families, the news may be disappointing, especially for those who have been waiting for new treatment options. For the field of psychedelic research, this trial serves as a reminder of the challenges involved in developing effective treatments. It highlights the need for rigorous scientific testing and the importance of not overstepping the bounds of current evidence. Atai Life Sciences has announced plans to continue reviewing the data from the trial to determine the next steps. This approach is prudent, given the potential that subgroup analyses or further research could uncover beneficial effects that were not immediately apparent. Ketamine is not the only psychedelic compound being explored for its therapeutic potential. Psilocybin, the active ingredient in magic mushrooms, and MDMA, commonly known as ecstasy, are also under investigation for their possible roles in treating mental health disorders. The journey of these substances from recreational drugs to potential therapeutic agents is a complex one, marked by both promise and challenge. The approval of Spravato, a drug based on ketamine, by the FDA in 2019 for the treatment of severe depression, marked a significant milestone in this journey. It demonstrated that, with rigorous testing and regulatory approval, psychedelic-derived medicines could enter the mainstream of psychiatric treatment. However, the path forward is not without its obstacles. Regulatory hurdles, public perception, and the need for high-quality clinical trials are just a few of the challenges that must be overcome. The recent trial results, while disappointing, are a part of this process. They contribute to the growing body of evidence that will eventually guide the development and use of psychedelic medicines. The latest trial results on ketamine's effectiveness in treating depression are a sobering reminder of the complexities and challenges inherent in psychiatric research. While they may dampen some of the enthusiasm surrounding psychedelic medicine, they do not diminish the potential that these substances hold. Instead, they underscore the importance of a cautious, evidence-based approach to developing new treatments. As the field of psychedelic medicine continues to evolve, it is crucial that researchers, clinicians, and patients remain committed to the principles of rigorous scientific inquiry and patient safety. The future of psychedelic medicine is promising, but it must be built on a foundation of solid evidence and careful consideration of both the benefits and the risks of these powerful substances.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
